Swiss Startup TECregen Aims to Regenerate Aging Immune Systems with $12.6M Seed Round

The thymus, a forgotten organ behind the breastbone, may hold the key to reversing immune aging—and one Swiss startup is betting $12.6 million on regenerating it.

TECregen has secured $12.6 million in seed funding to develop thymus-rejuvenating therapies targeting age-related immune decline.

The thymus, which trains T cells, undergoes involution with age, leading to weakened immune responses and increased vulnerability to infections, cancer, and vaccine failures.

TECregen’s 'thymopoietic' drugs aim to regenerate thymic epithelial cells using engineered growth factors to avoid systemic toxicity.

Harry Robb said:

'TECregen’s thymus-rejuvenating biologics address one of the fundamental drivers of immune aging, and their innovative approach has the potential to rebuild immune resilience and support healthy aging.'

Preclinical data show recovery of endogenous T-cell production in age- and disease-relevant models. Bo Rode Hansen noted:

'The company’s approach is supported by compelling preclinical biology across age- and disease-relevant models, demonstrating recovery of endogenous T-cell production.'

TECregen plans to advance preclinical data and initiate IND-enabling studies, focusing on clinical proof-of-concept in populations with measurable immune deficits.

The field includes prior efforts like Dr. Greg Fahy’s 2015 trial showing reduced epigenetic age via thymus regeneration. No independent expert critique was included in the source.

⚠️ LEGAL DISCLAIMER: It is for informational purposes only. It never substitutes for professional medical advice, diagnosis, or treatment. Always consult your doctor regarding any questions about your health.